Exploring 2,5-DMA. To explore a different substance…

Names:
2,5-DMA · DMA · DOH · 2,5-Dimethoxyamphetamine
IUPAC name:
1-(2,5-Dimethoxyphenyl)propan-2-amine
ID: 54 · Formula: C11H17NO2 · Molecular weight: 195.258
InChI: InChI=1S/C11H17NO2/c1-8(12)6-9-7-10(13-2)4-5-11(9)14-3/h4-5,7-8H,6,12H2,1-3H3

Glennon, RA; Titeler, M; McKenney, JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci., 17 Dec 1984, 35 (25), 2505–2511. 332 kB. http://dx.doi.org/10.1016/0024-3205(84)90436-3

Kanai, K; Takekawa, K; Kumamoto, T; Ishikawa, T; Ohmori, T. Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC-MS, and GC-MS. Forensic Toxicol., 1 Nov 2008, 26 (2), 6–12. 406 kB. http://dx.doi.org/10.1007/s11419-008-0041-2

Foster, BC; McLeish, J; Wilson, DL; Whitehouse, LW; Zamecnik, J; Lodge, BA. Biotransformation of tri-substituted methoxyamphetamines by Cunninghamella echinulata. Xenobiotica, 1992, 22 (12), 1383–1394. 765 kB. http://dx.doi.org/10.3109/00498259209056689

Bailey, K; Legault, D. 13C NMR spectra and structure of mono-, di- and trimethoxyphenylethylamines and amphetamines. Org. Magn. Resonance, 1 Jun 1983, 21 (6), 391–396. 680 kB. http://dx.doi.org/10.1002/omr.1270210611

Fenderson5555. Shulgin’s syntheses of 2,5-DMA, DOB and DOEF. 5 Dec 2011. 3.7 MB.

Glennon, RA; Liebowitz, SM; Anderson, GM. Serotonin receptor affinities of psychoactive phenalkylamine analogues. J. Med. Chem., 1 Mar 1980, 23 (3), 294–299. 844 kB. http://dx.doi.org/10.1021/jm00177a017

Altun, A; Golcuk, K; Kumru, M; Jalbout, AF. Electron-conformation study for the structure-hallucinogenic activity relationships of phenylalkylamines. Bioorg. Med. Chem., 1 Dec 2003, 11 (24), 3861–3868. 577 kB. http://dx.doi.org/10.1016/S0968-0896(03)00437-1

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1.1 MB. http://dx.doi.org/10.1021/jm00082a014

Guy, M; Freeman, S; Alder, JF; Brandt, SD. The Henry reaction: spectroscopic studies of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines. Cent. Eur. J. Chem., 1 Dec 2008, 6 (4), 526–534. 982 kB. http://dx.doi.org/10.2478/s11532-008-0054-z

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. http://dx.doi.org/10.1016/j.forsciint.2011.11.003

Ho, B; McIsaac, WM; An, R; Tansey, LW; Walker, KE; Englert, LF; Noel, MB. Analogs of α-methylphenethylamine (amphetamine). I. Synthesis and pharmacological activity of some methoxy and/or methyl analogs. J. Med. Chem., 1 Jan 1970, 13 (1), 26–30. 601 kB. http://dx.doi.org/10.1021/jm00295a007

Antun, F; Smythies, JR; Benington, F; Morin, RD; Barfknecht, CF; Nichols, DE. Native fluorescence and hallucinogenic potency of some amphetamines. Experientia, 15 Jan 1971, 27 (1), 62–63. 248 kB. http://dx.doi.org/10.1007/BF02137743

Shannon, M; Battaglia, G; Glennon, RA; Titeler, M. 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur. J. Pharmacol., 15 Jun 1984, 102 (1), 23–29. 461 kB. http://dx.doi.org/10.1016/0014-2999(84)90333-9

Bailey, K; Legauld, D; Verner, D. Spectroscopic and chromatographic identification of dimethoxyamphetamines. J. Assoc. Off. Anal. Chem., 1974, 57 (1), 70–78. 426 kB.

Shaler, RC; Padden, JJ. Identification of hallucinogens in illicit seizures I: 2,5-dimethoxyamphetamine. J. Pharm. Sci., 1 Nov 1972, 61 (11), 1851–1855. 334 kB. http://dx.doi.org/10.1002/jps.2600611142

Sreenivasan, V. Problems in Identification of Methylenedioxy and Methoxy Amphetamines. J. Crim. Law Criminol., 1 Jan 1972, 63 (2), 304. 996 kB.

Glennon, RA; Rosecrans, JA; Young, R. Behavioral properties of psychoactive phenylisopropylamines in rats. Eur. J. Pharmacol., 17 Dec 1981, 76 (4), 353–360. 964 kB. http://dx.doi.org/10.1016/0014-2999(81)90106-0

Glennon, RA; Seggel, MR. Interaction of phenylisopropylamines with central 5-HT2 receptors. Analysis by quantitative structure-activity relationships. In Probing Bioactive Mechanisms; ACS Symposium Series; Magee, PS; Henry, DR; Block, JH, Eds., American Chemical Society, Washington, DC, 14 Nov 1989; Vol. 413, pp 264–280. 4.4 MB. http://dx.doi.org/10.1021/bk-1989-0413.ch018

Runyon, SP; Mosier, PD; Roth, BL; Glennon, RA; Westkaemper, RB. Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: A ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. J. Med. Chem., 2008, 51 (21), 6808–2828. 2.2 MB. http://dx.doi.org/10.1021/jm800771x

Shulgin, AT. Psychotomimetic drugs: structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1978; Vol. 11, pp 243–333. 2.6 MB. http://dx.doi.org/10.1007/978-1-4757-0510-2_6 Rhodium.

Glennon, RA; Young, R; Rosecrans, JA. A comparison of the behavioral effects of DOM homologs. Pharmacol. Biochem. Behav., 1 Apr 1982, 16 (4), 557–559. 256 kB. http://dx.doi.org/10.1016/0091-3057(82)90414-2

Nichols, DE; Snyder, SE; Oberlender, R; Johnson, MP; Huang, X. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J. Med. Chem., 1 Jan 1991, 34 (1), 276–281. 833 kB. http://dx.doi.org/10.1021/jm00105a043

Nichols, DE; Barfknecht, CF; Rusterholz, DB; Benington, F; Morin, RD. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J. Med. Chem., 1 Jan 1973, 16 (5), 480–483. 515 kB. http://dx.doi.org/10.1021/jm00263a013

Dyer, DC; Nichols, DE; Rusterholz, DB; Barfknecht, CF. Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines. Life Sci., 1 Oct 1973, 13 (7), 885–896. 398 kB. http://dx.doi.org/10.1016/0024-3205(73)90079-9

Scorza, M; Carrau, C; Silveira, R; Zapata-Torres, G; Cassels, BK; Reyes-Parada, M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem. Pharmacol., 15 Dec 1997, 54 (12), 1361–1369. 697 kB. http://dx.doi.org/10.1016/S0006-2952(97)00405-X

Moya, PR; Berg, KA; Gutiérrez-Hernandez, MA; Sáez-Briones, P; Reyes-Parada, M; Cassels, BK; Clarke, WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther., 1 Jun 2007, 321 (3), 1054–1061. 188 kB. http://dx.doi.org/10.1124/jpet.106.117507

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3), 364–381. 817 kB. http://dx.doi.org/10.1016/j.neuropharm.2011.01.017

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. http://dx.doi.org/10.1002/cmdc.200800133

Nelson, DL; Lucaites, VL; Wainscott, DB; Glennon, RA. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. N-S. Arch. Pharmacol., 1 Jan 1999, 359 (1), 1–6. 66 kB. http://dx.doi.org/10.1007/PL00005315

Aldous, FAB; Barrass, BC; Brewster, K; Buxton, DA; Green, DM; Pinder, RM; Rich, P; Skeels, PM; Tutt, KJ. Structure-activity relationships in psychotomimetic phenylalkylamines. J. Med. Chem., 1 Oct 1974, 17 (10), 1100–1111. 1.2 MB. http://dx.doi.org/10.1021/jm00256a016

Parker, MA; Kurrasch, DM; Nichols, DE. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem., 1 Jan 2008, 16 (8), 4661–4669. 296 kB. http://dx.doi.org/10.1016/j.bmc.2008.02.033

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8.4 MB.

Shulgin, AT; Dyer, DC. Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines. J. Med. Chem., 1 Jan 1975, 18 (12), 1201–1204. 534 kB. http://dx.doi.org/10.1021/jm00246a006

Acuña-Castillo, C; Villalobos, C; Moya, PR; Sáez, P; Cassels, BK; Huidobro-Toro, JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol., 1 Jun 2002, 136 (4), 510–519. 232 kB. http://dx.doi.org/10.1038/sj.bjp.0704747

Glennon, RA; Dukat, M; Grella, B; Hong, S; Costantino, L; Teitler, M; Smith, C; Egan, C; Davis, K; Mattson, MV. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend., 1 Aug 2000, 60 (2), 121–132. 276 kB. http://dx.doi.org/10.1016/S0376-8716(99)00148-9

White, TJ; Goodman, D; Shulgin, AT; Castagnoli, N; Lee, R; Petrakis, NL. Mutagenic activity of some centrally active aromatic amines in Salmonella typhimurium. Mutat. Res., 1 Jan 1977, 56 (2), 199–202. 256 kB. http://dx.doi.org/10.1016/0027-5107(77)90210-X

Domelsmith, LN; Eaton, TA; Houk, KN; Anderson, GM; Glennon, RA; Shulgin, AT; Castagnoli, N; Kollman, PA. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues. J. Med. Chem., 1 Jan 1981, 24 (12), 1414–1421. 963 kB. http://dx.doi.org/10.1021/jm00144a009

Nichols, DE; Shulgin, AT; Dyer, DC. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sci., 1 Jan 1977, 21 (4), 569–576. 320 kB. http://dx.doi.org/10.1016/0024-3205(77)90099-6

Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1970; pp 21–41. 8.6 MB.

Shulgin, AT; Sargent, T; Naranjo, C. Structure-activity relationships of one-ring psychotomimetics. Nature, 1 Jan 1969, 221, 537–541. 537 kB. http://dx.doi.org/10.1038/221537a0

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 1 Jan 2007, 72 (5), 1200–1209. 487 kB. http://dx.doi.org/10.1124/mol.107.039255

Seggel, MR; Yousif, MY; Lyon, RA; Titeler, M; Roth, BL; Suba, EA; Glennon, RA. A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J. Med. Chem., 1 Mar 1990, 33 (3), 1032–1036. 807 kB. http://dx.doi.org/10.1021/jm00165a023

Glennon, RA; Bondarev, ML; Khorana, N; Young, R. β-Oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med. Chem., 1 Jan 2004, 47 (24), 6034–6041. 146 kB. http://dx.doi.org/10.1021/jm040082s

2,5-DMMA · METHYL-DMA
2,5-DNNA
DEDMA
2,5-DMA-Ac
1540
N-Acetyl 2,5-DMA
2C-H
4C-DMA · 4C-H
α-Carboxy-2C-H
β-HO-2,5-DMA
2-Br-5-MA
2-I-5-MA
2,5-HMA
TMA-4
3-DOB
3-DON
3-DOM
3,2,5-DOET
ALEPH
ALEPH-2
ALEPH-4
ALEPH-6
ALEPH-7
DOAM
DOB
DOBU
DOC
DOEF
DOET
DOI
DOM
DON
DOPR
MEM
MPM
TMA-2
DOF
DOIB
DOTB
DOSB
DONH · DOA
DOAA
Hydroxy-DOPR
DOIP
MIPM
MBM
MAM
DOHE
DOBZ
DOCPM
ALEPH-8
ALEPH-5
ALEPH-16
ALEPH-21
DOTFM
2328
DOYN
DOCN
DOPh3
2325
2329
2330
DOVI
DOAC
DOCA
DOOH
DOCONHP
DOCOE
DOCEB
DOCEP
DOOC
DODMeA
DOFM
DOHM
DOHP
DONO
DOEH
M(2OP)M
M(3OP)M
MBZM
ALEPH-19
ALEPH-S-amyl
ALEPH-S-PhEt
ALEPH sulfone
DOTFE
MTFEM
MDFEM
MFEM
DOBM
DOMCl
DOCET
DOTFPR
DOHSM
DOMSM
DOMOM
DONCO
DONCOE
DONCOTFM
DOCNM
1016
2-MA · 2-Methoxyamphetamine
2134
5-I-2-MA
5HMA
2CLisaH
5,8-ADT
2,5-DMA-βk · 2,5-Dimethoxycathinone
2,5-DMPEA-βk
2,5-DMAI
1146
2,3-DMBZP · 2,5-DMBZP
936
937
939
940
2C-D
DESOXY
2,4-DMA
3,4-DMA
MEPEA
3,5-DMA
2,3-DMA
2,6-DMA
MM-GEA
N-Me-2,5-DMPEA · 25H-NMe
2,5-MH-MMA
2-DES-Me-DOM · 2-DM-DOM
5-DES-Me-DOM · 5-DM-DOM
4-Me-2,6-DMPEA · ψ-2C-D
2407
4-Ethoxynorephedrine
BO3MM
BO3ME
BO3MA
BO3E
N-Me-DMPEA-2
2,3-EMPEA
N-Me-DMPEA-3
2,4-EMPEA
Coryneine
N,N-Me-DHA
DHEA
MHMA
MH-α-Et-PEA
HMMA
β-Me-DMPEA
N-Me-DMPEA
EMPEA
β,2-HO-5,N-DMeA
β-HO-N-Me-2-M-5-MePEA
β-HO-2-M-5-MeA
N,N-Me-2,5-HMPEA
β-Me-2,5-DMPEA
N-Me-3,5-DMPEA
N-Me-2,6-DMPEA
6-Me-2,4-DMPEA
iso-2C-D
HMP
homo-3,4-DMPEA
N-MeO-PMA
2,5-DMMA · METHYL-DMA
2,5-DNNA
DEDMA
2,5-DMA-Ac
1540
N-Acetyl 2,5-DMA
2C-H
4C-DMA · 4C-H
α-Carboxy-2C-H
β-HO-2,5-DMA
2-Br-5-MA
2-I-5-MA
2,5-HMA
TMA-4
3-DOB
3-DON
3-DOM
3,2,5-DOET
ALEPH
ALEPH-2
ALEPH-4
ALEPH-6
ALEPH-7
DOAM
DOB
DOBU
DOC
DOEF
DOET
DOI
DOM
DON
DOPR
MEM
MPM
TMA-2
DOF
DOIB
DOTB
DOSB
DONH · DOA
DOAA
Hydroxy-DOPR
DOIP
MIPM
MBM
MAM
DOHE
DOBZ
DOCPM
ALEPH-8
ALEPH-5
ALEPH-16
ALEPH-21
DOTFM
2328
DOYN
DOCN
DOPh3
2325
2329
2330
DOVI
DOAC
DOCA
DOOH
DOCONHP
DOCOE
DOCEB
DOCEP
DOOC
DODMeA
DOFM
DOHM
DOHP
DONO
DOEH
M(2OP)M
M(3OP)M
MBZM
ALEPH-19
ALEPH-S-amyl
ALEPH-S-PhEt
ALEPH sulfone
DOTFE
MTFEM
MDFEM
MFEM
DOBM
DOMCl
DOCET
DOTFPR
DOHSM
DOMSM
DOMOM
DONCO
DONCOE
DONCOTFM
DOCNM
1016
2-MA · 2-Methoxyamphetamine
2134
5-I-2-MA
5HMA
2CLisaH
5,8-ADT
2,5-DMA-βk · 2,5-Dimethoxycathinone
2,5-DMPEA-βk
2,5-DMAI
1146
2,3-DMBZP · 2,5-DMBZP
936
937
939
940
2C-D
DESOXY
2,4-DMA
3,4-DMA
MEPEA
3,5-DMA
2,3-DMA
2,6-DMA
MM-GEA
N-Me-2,5-DMPEA · 25H-NMe
2,5-MH-MMA
2-DES-Me-DOM · 2-DM-DOM
5-DES-Me-DOM · 5-DM-DOM
4-Me-2,6-DMPEA · ψ-2C-D
2407
4-Ethoxynorephedrine
BO3MM
BO3ME
BO3MA
BO3E
N-Me-DMPEA-2
2,3-EMPEA
N-Me-DMPEA-3
2,4-EMPEA
Coryneine
N,N-Me-DHA
DHEA
MHMA
MH-α-Et-PEA
HMMA
β-Me-DMPEA
N-Me-DMPEA
EMPEA
β,2-HO-5,N-DMeA
β-HO-N-Me-2-M-5-MePEA
β-HO-2-M-5-MeA
N,N-Me-2,5-HMPEA
β-Me-2,5-DMPEA
N-Me-3,5-DMPEA
N-Me-2,6-DMPEA
6-Me-2,4-DMPEA
iso-2C-D
HMP
homo-3,4-DMPEA
N-MeO-PMA
18 October 2017 · Creative Commons BY-NC-SA ·